Researchers at the Faculty of Pharmacy have developed PeptiENV, a cancer vaccine platform, which can be used to improve the therapeutic efficacy of oncolytic enveloped viruses currently in clinical use. With the help of this new cancer vaccine platform, the activation of the human immune response against cancer cells becomes significantly more effective.
"What is actually the most remarkable insight concerning the PeptiENV cancer vaccine platform is that we are able to envelop oncolytic viruses with the patient's own cancer peptides, enabling tailored targeted treatment," says Erkko Ylösmäki, an Academy of Finland post-doctoral researcher working in the ImmunoViroTherapy Lab of the Faculty of Pharmacy, University of Helsinki.
Oncolytic viruses are naturally occurring viruses that have been modified to restrict their division into cancer cells only. Virotherapy is usually administered as an injection to the tumour or the abdominal cavity, or intravenously.
A virus enveloped with peptides through the PeptiENV platform can effectively "train" the patient's own, locally active T cells to identify tumour cells. Thus, the amount of T cells able to identify tumour cells increases in the cancerous tissue, improving the efficacy of the cancer therapy.
The study demonstrated the functionality of the PeptiENV cancer vaccine platform in conjunction with oncolytic enveloped herpes simplex virus 1, already used in the treatment of metastatic melanoma. Oncolytic vaccinia viruses, among others currently under investigation in clinical trials, are also compatible with the cancer vaccine platform.
Additionally, the number of T cells in the cancerous tissue that are able to identify cancer cells strongly correlates with the therapeutic effect of new immune checkpoint inhibitors.
"We aim to expand the pool of patients that could potentially benefit from the unparalleled efficacy of immune checkpoint inhibitors," Ylösmäki explains.
Erkko Ylosmaki | EurekAlert!
New approach for targeted cancer immunotherapy
30.07.2020 | Universität Basel
A new way to target cancers using 'synthetic lethality'
28.07.2020 | University of California - San Diego
Traditional single-cell sequencing methods help to reveal insights about cellular differences and functions - but they do this with static snapshots only...
“Core-shell” clusters pave the way for new efficient nanomaterials that make catalysts, magnetic and laser sensors or measuring devices for detecting electromagnetic radiation more efficient.
Whether in innovative high-tech materials, more powerful computer chips, pharmaceuticals or in the field of renewable energies, nanoparticles – smallest...
An international research team with Prof. Cornelia Denz from the Institute of Applied Physics at the University of Münster develop for the first time light fields using caustics that do not change during propagation. With the new method, the physicists cleverly exploit light structures that can be seen in rainbows or when light is transmitted through drinking glasses.
Modern applications as high resolution microsopy or micro- or nanoscale material processing require customized laser beams that do not change during...
Although no life has been detected on the Martian surface, a new study from astrophysicist and research scientist at the Center for Space Science at NYU Abu...
New approach creates synthetic layered magnets with unprecedented level of control over their magnetic properties
The magnetic properties of a chromium halide can be tuned by manipulating the non-magnetic atoms in the material, a team, led by Boston College researchers,...
23.07.2020 | Event News
21.07.2020 | Event News
07.07.2020 | Event News
04.08.2020 | Life Sciences
04.08.2020 | Medical Engineering
04.08.2020 | Ecology, The Environment and Conservation